Literature DB >> 24415648

Insights into wild-type and mutant p53 functions provided by genetically engineered mice.

Lawrence A Donehower1.   

Abstract

Recent whole-exome sequencing studies of numerous human cancers have now conclusively shown that the TP53 tumor-suppressor gene is the most frequently mutated gene in human cancers. Despite extensive studies of the TP53 gene and its encoded protein (p53), our understanding of how TP53 mutations contribute to cancer initiation and progression remain incomplete. Genetically engineered mice with germline or inducible Trp53 somatic mutations have provided important insights into the mechanisms by which different types of p53 mutation influence cancer development. Trp53 germline mutations that alter specific p53 structural domains or posttranslation modification sites have benefitted our understanding of wild-type p53 functions in a whole organism context. Moreover, genetic approaches to reestablish functional wild-type p53 to p53-deficient tissues and tumors have increased our understanding of the therapeutic potential of restoring functional p53 signaling to cancers. This review outlines many of the key insights provided by the various categories of Trp53 mutant mice that have been generated by multiple genetic engineering approaches.
© 2014 WILEY PERIODICALS, INC.

Entities:  

Keywords:  TP53; Trp53; genetically engineered mice; mouse cancer models; p53

Mesh:

Substances:

Year:  2014        PMID: 24415648     DOI: 10.1002/humu.22507

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  12 in total

1.  Whole-genome sequencing analysis of phenotypic heterogeneity and anticipation in Li-Fraumeni cancer predisposition syndrome.

Authors:  Hany Ariffin; Pierre Hainaut; Anna Puzio-Kuter; Soo Sin Choong; Adelyne Sue Li Chan; Denis Tolkunov; Gunaretnam Rajagopal; Wenfeng Kang; Leon Li Wen Lim; Shekhar Krishnan; Kok-Siong Chen; Maria Isabel Achatz; Mawar Karsa; Jannah Shamsani; Arnold J Levine; Chang S Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-13       Impact factor: 11.205

Review 2.  Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others.

Authors:  Kanaga Sabapathy; David P Lane
Journal:  Nat Rev Clin Oncol       Date:  2017-09-26       Impact factor: 66.675

Review 3.  Mutant TP53 posttranslational modifications: challenges and opportunities.

Authors:  Thuy-Ai Nguyen; Daniel Menendez; Michael A Resnick; Carl W Anderson
Journal:  Hum Mutat       Date:  2014-02-11       Impact factor: 4.878

Review 4.  The Roles of MDM2 and MDMX in Cancer.

Authors:  Orit Karni-Schmidt; Maria Lokshin; Carol Prives
Journal:  Annu Rev Pathol       Date:  2016-03-17       Impact factor: 23.472

5.  Allele, phenotype and disease data at Mouse Genome Informatics: improving access and analysis.

Authors:  Susan M Bello; Cynthia L Smith; Janan T Eppig
Journal:  Mamm Genome       Date:  2015-07-11       Impact factor: 2.957

Review 6.  The Contrived Mutant p53 Oncogene - Beyond Loss of Functions.

Authors:  Kanaga Sabapathy
Journal:  Front Oncol       Date:  2015-12-10       Impact factor: 6.244

7.  The impact of p53 on DNA damage and metabolic activation of the environmental carcinogen benzo[a]pyrene: effects in Trp53(+/+), Trp53(+/-) and Trp53(-/-) mice.

Authors:  Annette M Krais; Ewoud N Speksnijder; Joost P M Melis; Radek Indra; Michaela Moserova; Roger W Godschalk; Frederik-J van Schooten; Albrecht Seidel; Klaus Kopka; Heinz H Schmeiser; Marie Stiborova; David H Phillips; Mirjam Luijten; Volker M Arlt
Journal:  Arch Toxicol       Date:  2015-05-21       Impact factor: 5.153

8.  Metabolic activation of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine and DNA adduct formation depends on p53: Studies in Trp53(+/+),Trp53(+/-) and Trp53(-/-) mice.

Authors:  Annette M Krais; Ewoud N Speksnijder; Joost P M Melis; Rajinder Singh; Anna Caldwell; Gonçalo Gamboa da Costa; Mirjam Luijten; David H Phillips; Volker M Arlt
Journal:  Int J Cancer       Date:  2015-09-22       Impact factor: 7.396

Review 9.  Dysregulation of microRNA biogenesis in cancer: the impact of mutant p53 on Drosha complex activity.

Authors:  Aymone Gurtner; Emmanuela Falcone; Francesca Garibaldi; Giulia Piaggio
Journal:  J Exp Clin Cancer Res       Date:  2016-03-12

10.  Interference with mutagenic aflatoxin B1-induced checkpoints through antagonistic action of ochratoxin A in intestinal cancer cells: a molecular explanation on potential risk of crosstalk between carcinogens.

Authors:  Juil Kim; Seong-Hwan Park; Kee Hun Do; Dongwook Kim; Yuseok Moon
Journal:  Oncotarget       Date:  2016-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.